Suven Life Sciences completes Phase 2 study of SUVN-502 for moderate Alzheimer’s disease

23 May 2019 Evaluate

Suven Life Sciences has completed last patient last visit (LPLV) for its Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease. The company expects to report the top-line data of this study at Alzheimer’s Association International Conference (AAIC) on July 17, 2019 at Los Angeles.

This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of Masupirdine (SUVN-502) in moderate Alzheimer’s Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients. There is an urgent need for treatment options for patients with Alzheimer’s disease (AD) dementia since there are no new drugs discovered or developed since 2003.

Completing this trial represents a significant milestone for the development of company’s lead compound Masupirdine (SUVN-502) in this Phase 2 study in moderate Alzheimer’s disease and moves it a step closer to potentially bringing this new treatment option for people afflicted with moderate Alzheimer’s disease globally.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.

Suven Life Sciences Share Price

163.05 -3.00 (-1.81%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×